AbbVie Inc. (ABBV) Stock Analysis

Skyrizi and Rinvoq each exceeded 10% of AbbVie's total net revenues in 2025, together accounting for approximately 42% of consolidated net revenues. Three AbbVie products — Imbruvica, Vraylar, and Botox — have been selected for Medicare government-set pricing under the Inflation Reduction Act, with effective dates of January 2026, January 2027, and January 2028 respectively. AbbVie's portfolio spans immunology, neuroscience, oncology, aesthetics, and eye care, marketed through dedicated commercial organizations across major global markets.

AbbVie generates revenue through wholesale distributors; McKesson Corporation, Cardinal Health, and Cencora collectively handle substantially all U.S. pharmaceutical product sales, with no individual wholesaler exceeding 43% of 2025 gross U.S. revenues. Outside the U.S., the company sells primarily through wholesalers and distributors, working with centralized national payer systems on reimbursement terms. Immunology products including Skyrizi, Rinvoq, and Humira compete against IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, biosimilars, and other products. In January 2026, AbbVie entered a voluntary agreement with the U.S. government to provide pricing concessions and U.S.-based research and capital investments in exchange for exemptions from tariffs and future pricing mandates for a three-year period. Manufacturing of biologics is complex and may rely on single-source suppliers for certain raw materials, with finding alternative sources potentially requiring significant time and regulatory approvals.